Related references
Note: Only part of the references are listed.Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
Matthew D. Hellmann et al.
CLINICAL CANCER RESEARCH (2021)
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma et al.
CANCER DISCOVERY (2021)
A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy
X. Guan et al.
ANNALS OF ONCOLOGY (2021)
Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)
E. T. Roussos Torres et al.
ANNALS OF ONCOLOGY (2021)
EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers - phase IIA dose finding
E. Cartwright et al.
ANNALS OF ONCOLOGY (2021)
Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) plus entinostat (entino) in MORPHEUS-HR plus breast cancer (M-HR plus BC)
A. Sonnenblick et al.
ANNALS OF ONCOLOGY (2021)
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)
Evanthia T. Roussos Torres et al.
CLINICAL CANCER RESEARCH (2021)
Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).
Priyanka Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.
Jessica Cecile Hassel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
Dimitrios Goutas et al.
DIAGNOSTICS (2021)
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
E. de Guillebon et al.
ESMO OPEN (2021)
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Cristina P. Rodriguez et al.
CLINICAL CANCER RESEARCH (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.
Roberto Pili et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
Andreas Nicholas Saltos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).
Joyce O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The roles of histone variants in fine-tuning chromatin organization and function
Sara Martire et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Manuela Terranova-Barberio et al.
NATURE COMMUNICATIONS (2020)
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
Andressa S. Laino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The roles of DNA, RNA and histone methylation in ageing and cancer
Ewa M. Michalak et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox et al.
SCIENTIFIC REPORTS (2019)
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2019)
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models
Sida Shen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
Ryan J. Sullivan et al.
CANCER RESEARCH (2019)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Epigenetic mechanisms of tumor resistance to immunotherapy
Natalia Arenas-Ramirez et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
Cathrin Ritter et al.
SCIENTIFIC REPORTS (2017)
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper et al.
CELL (2017)
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Ashley Orillion et al.
CLINICAL CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Epigenetic balance of gene expression by Polycomb and COMPASS families
Andrea Piunti et al.
SCIENCE (2016)
The epigenetic landscape of T cell exhaustion
Debattama R. Sen et al.
SCIENCE (2016)
Digging deep into dirty'' drugs - modulation of the methylation machinery
Lisa Pleyer et al.
DRUG METABOLISM REVIEWS (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function
Eva Sahakian et al.
MOLECULAR IMMUNOLOGY (2015)
Function and information content of DNA methylation
Dirk Schuebeler
NATURE (2015)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li et al.
ONCOTARGET (2014)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
Matthew J. Sweet et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Jeremy Schwartzentruber et al.
NATURE (2012)
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson et al.
NATURE CHEMICAL BIOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Histone deacetylases as regulators of inflammation and immunity
Melanie R. Shakespear et al.
TRENDS IN IMMUNOLOGY (2011)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
Cheng-Jung Lai et al.
CANCER RESEARCH (2010)
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors
Yoshifumi Baba et al.
MOLECULAR CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules
Sara J. Adair et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Deacetylase inhibition promotes the generation and function of regulatory T cells
Ran Tao et al.
NATURE MEDICINE (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
The 8; 21 translocation in leukemogenesis
LF Peterson et al.
ONCOGENE (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
